You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽託生物(300583.SZ)業績快報:2019年淨利降57.28%至5386.19萬元
格隆匯 02-28 16:41

格隆匯2月28日丨賽託生物(300583.SZ)披露2019年年度業績快報,實現營業總收入9.69億元,同比下降7.94%;利潤總額6737.0萬元,同比下降54.72%;歸屬於上市公司股東的淨利潤5386.19萬元,同比下降57.28%;基本每股收益0.5元。

上述指標變動的主要原因系:(1)報告期內收入指標較上年同比略有下降,主要原因系產品價格短期波動所致。

(2)報告期內研發投入較上年同比增加23%,報告期內,公司在研項目推進提速的同時,進一步加大新產品的研發投入,全年研發支出4856.00萬元,較上年同比增加913.90萬元。

(3)報告期內公司持續推進轉型升級,導致管理費用等成本項增加,隨着公司規模的不斷擴大,公司將發展戰略調整為“致力於將公司打造成集醫藥中間體、原料藥和成品製劑為一體的生物技術企業”。報告期內,公司推動甾體類高端原料藥及中間體項目順利落地的同時收購意大利LISA製藥公司,實現了由基礎原料生產到終端製劑產品研製的全產業鏈戰略佈局。報告期內,公司加強了與原料藥和製劑產品相關的人員配備、質量體系搭建,從而導致與之相關的各類成本均有不同程度的增加。

(4)基本每股收益較上年同比下降57.63%,主要系歸屬於上市公司股東的淨利潤變化所致。

(5)加權平均淨資產收益率較上年同比下降4.36個百分點,主要系利潤總額減少和公司加權平均淨資產增加雙重因素影響所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account